Posted by: admin on: December 6, 2011
A selective estrogen receptor modulator (SERM) bazedoxifene is on the trial, to be approved as a drug for prevention of postmenopausal osteoporosis. Here is an article showing the clinical efficacy and safety of bazedoxifene in the treatment of postmenopausal osteoporosis. Team@CMHF
Posted by: admin on: December 6, 2011
The new calcium channel blocker azelnidipine found to have an added effect on Olmesartan action on hypertensive diabetic patients, has an advantage in chronic kidney patients. Here is the study. Team@CMHF
Posted by: admin on: December 5, 2011
ARBs are the most commonly used Antihypertensives because of their renal protective benefit. But here is a new study stating its cardiac risk & cancer susceptablity. But if benefit out weighs their safety concerns we still have the choice. Team@CMHF
Posted by: admin on: December 5, 2011
Antibiotic resistance has become a serious problem since they are greatly misused. This is due to its purchase over the counter in many countries like ours and it being taken in sub optimal doses or the course not being completed. We are in a grave situation. Read on to know more. Team@CMHF
Posted by: admin on: December 5, 2011
As the life expectancy is on an upscale trend, Dementia and subsequent Alzheimer’s is becoming a common finding Guidelines to detect hallmarks of this disease before the symptoms will be a grear breakthrough in Geriatric medicine. But these findings may not be of great use now as it is still at the research stage. Nevertheless […]